Medicine and Dentistry
Ganglioglioma
100%
Glioblastoma
78%
Neoplasm
69%
Prostate Cancer
59%
Radiation Therapy
48%
Breast Cancer
33%
Neuro-Oncology
28%
Tumor Cell
26%
Angiogenesis
19%
Overall Survival
17%
Urinary System
17%
Quality of Life
17%
Isocitrate Dehydrogenase 1
15%
Androgen Deprivation Therapy
14%
Cancer Stem Cell
14%
Microvessel
14%
Prognostic Factor
14%
Junctional Adhesion Molecule A
13%
Prostatectomy
13%
Temozolomide
12%
Adverse Event
12%
Malignant Neoplasm
12%
Multivariate Analysis
11%
Promoter Region
11%
Diagnosis
10%
Pelvic Floor
10%
Stem Cell
9%
Protein Expression
9%
Cell Marker
8%
Cancer Therapy
8%
Pelvis
8%
Image Analysis
8%
Patient-Reported Outcome
8%
Surgery
8%
Nestin
8%
Biological Marker
7%
Cohort Analysis
7%
Macrophage
7%
Cancer
6%
Disease
6%
Glioma Cell
6%
Phosphotransferase
6%
Fluorine-18
6%
Positron Emission Tomography
6%
Urokinase
6%
Microglia
6%
Methyltransferase
6%
Cabazitaxel
6%
Castration Resistant Prostate Cancer
6%
Macroadenoma
6%
Pharmacology, Toxicology and Pharmaceutical Science
Glioblastoma
85%
Neoplasm
63%
Prostate Cancer
41%
Castration Resistant Prostate Cancer
39%
Overall Survival
38%
Docetaxel
34%
Breast Cancer
33%
Temozolomide
32%
Bevacizumab
26%
Irinotecan
26%
Cabazitaxel
19%
Progression Free Survival
17%
Malignant Neoplasm
15%
Prednisone
14%
Placebo
13%
Ipilimumab
13%
Plasminogen Activator Inhibitor 1
13%
Phase II Trials
13%
Mitoxantrone
12%
Chemotherapy
12%
Adverse Event
11%
Prevalence
9%
Recurrent Disease
8%
DNA Methyltransferase
8%
Androgen
7%
Methylated DNA Protein Cysteine Methyltransferase
7%
Intracranial Tumor
7%
Clinical Trial
6%
Fluorine 18
6%
Statin (Protein)
6%
Chemoradiation Therapy
6%
Tissue Inhibitor of Metalloproteinase 1
6%
Glioma
6%
Methyltransferase
6%
Gemcitabine
6%
Macroadenoma
6%
Urokinase
6%
Open-Label Trial
6%
Carcinoma
6%
Nestin
6%
Isocitrate Dehydrogenase 1
6%
Cetuximab
6%
Cell Marker
6%
Inert Gas
6%
Disease
5%
Prostate Specific Membrane Antigen
5%
Biochemistry, Genetics and Molecular Biology
Multivariate Analysis
29%
Overall Survival
24%
Cancer Stem Cell
22%
Isocitrate Dehydrogenase
19%
Methylation
17%
Promoter Region
14%
CD133
13%
Angiogenesis
13%
Immunofluorescence
11%
RNA-binding Protein
7%
Protein Expression
7%
DNA Methyltransferase
7%
Metalloprotease Inhibitor
6%
Plasminogen Activator Inhibitor-1
6%
Cell Membrane
6%
Phosphotransferase
6%
Kinase
6%
Biomarker Study
6%
Digital Pathology
6%
Tyrosine Kinase Receptor
6%
Methyltransferase
6%
Genetics
6%
Next Generation Sequencing
6%
Low Drug Dose
6%
Bevacizumab
6%
Macrophage
6%
Rebreathing
6%
Medical Record
6%
Stem Cell Marker
6%
Microglia
6%
Twin Study
6%
Heart Output
6%
Glycosylase
6%
Vitamin C
6%
Flow Cytometry
6%
Cell Adhesion Proteins
6%
Tumor-Associated Macrophage
5%
Progression Free Survival
5%
